A preclinical model of Vero-E6 cells, infected with SARS-CoV-2, isolated from a nasopharyngeal sample of COVID-19 patient, demonstrated the efficacy of human recombinant soluble ACE2 (hrsACE2) in inhibiting viral replication in a dose-dependent manner. This evidence concerns the gene ACE2 and COVID-19.